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ABSTRACT
Melanoma is an aggressive skin cancer; an early detection of the primary tumor 
may improve its prognosis. Despite many genes have been shown to be involved in 
melanoma, the full framework of melanoma transformation has not been completely 
explored. The characterization of pathways involved in tumor restraint in in vitro 
models may help to identify oncotarget genes. We therefore aimed to probe novel 
oncotargets through an integrated approach involving proteomic, gene expression 
and bioinformatic analysis 
We investigated molecular modulations in melanoma cells treated with ascorbic 
acid, which is known to inhibit cancer growth at high concentrations. For this purpose 
a proteomic approach was applied. A deeper insight into ascorbic acid anticancer 
activity was achieved; the discovery of deregulated processes suggested further 
biomarkers. In addition, we evaluated the expression of identified genes as well as 
the migration ability in several melanoma cell lines. 
Data obtained by a multidisciplinary approach demonstrated the involvement 
of Enolase 1 (ENO1), Parkinsonism-associated deglycase (PARK7), Prostaglansin 
E synthase 3 (PTGES3), Nucleophosmin (NPM1), Stathmin 1 (STMN1) genes in cell 
transformation and identified Single stranded DNA binding protein 1 (SSBP1) as a 
possible onco-suppressor in melanoma cancer.
INTRODUCTION
Malignant melanoma (MM) has been considered 
a rare cancer for a long time. However, in the last 
years incidence of MM has increased considerably 
in consequence of lifestyle and environmental 
changes. The mortality rate for MM is very high as it 
is highly invasive and also genetically resistant to 
chemotherapeutic treatments. The use of cytokines has 
been considered an effective tool against melanoma 
thanks to their ability to stimulate the immune system. 
In fact, an immunological pathogenetic mechanism 
has been suggested to be involved in the natural 
regression occurring in the primary tumor. Recently, the 
opportunity to characterize this cancer at the molecular 
level has improved therapeutical strategies, yet biased 
by chemoresistance. The molecular aspects underlying 
chemoresistance acquisition are unknown. Many studies, 
performed in animal models and in primary tumors, shed 
light on the complex genomic background involved in 
metastatic progression of MM; it has also been reported 
that mutation rate and gene modulation in melanoma 
are higher than in other solid malignancies [1, 2]. With 
the aims of: i) identifying oncotargets and ii) studying 
proteome variations involved in an antitumor activity, 
we investigated the pathways modulated by ascorbic 
acid (AsA) in melanoma cells [3]. It has been actually 
demonstrated in vitro that AsA reduces the malignant 
potential [4, 5] in a murine melanoma model [6] as well 
as in human melanoma [3].
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It should first be emphasized that ascorbic acid 
acts as a co-factor in many biological reactions and 
is an essential water-soluble vitamin with antioxidant 
properties. Recent pharmacokinetics studies demonstrated 
that intravenously administered AsA reaches high plasma 
levels leading to tumor cytotoxicity. It is important to 
note that AsA affects tumor cells selectively. Antioxidant 
levels reduction [7–9] as well as an increased glycolytic 
metabolism leading to DHA intracellular uptake [8] plus 
a higher sensitivity to H2O2, represent useful selective 
markers in cancer cells [10]. In our study, we analyzed 
proteome modulation in melanoma cells treated with AsA; 
gene expression levels for the identified proteins were then 
investigated as well as the migratory ability in several 
melanoma cells.
RESULTS
Proteomic profiling of melanoma cancer cells 
treated with AsA
In order to evaluate protein modulations by a 
molecule known to affect melanoma cells, we treated the 
MeWo and A375 cell lines with high concentrations of 
Ascorbic Acid. Our data showed a statistically significant 
dose-dependent reduction of cell viability in both cell lines 
at the highest concentrations used, i.e. 500 and 1000 μM, 
(Figure 1A). 
On the basis of cell viability data, we chose to 
analyze the total proteome of MeWo cells before and 
after treatment with 500 µM AsA for 48 h, which was 
shown to inhibit cancer growth. An average of 371 
(± 3%) protein spots with an apparent molecular mass 
between 10 and 200 kDa and a pI between 3 and 10 
were detected by 2-DE. Representative two-dimensional 
maps of the two conditions are reported in Figure 1B. 
Multivariate statistical analysis was applied to the protein 
patterns in order to identify protein species responsible for 
correlated variations and to investigate intra- and inter-
group relationships. PCA indicated two distinct groups of 
maps from the two experimental conditions, treated and 
untreated cells (Figure 1C). The strongest separation was 
observed in the first and second PCs, which accounted for 
most of the variation in the data sets, i.e. 22.6% and 19.2% 
respectively. These results indicate that natural variation 
in the proteomes is sufficient to allow discrimination 
between different groups, increasing the confidence that 
potential disease biomarkers and oncotargets can be found 
in this dataset. 
Supported by multivariate and univariate analyses, 
a total of 34 spots from the 2-DE analysis were identified 
as significantly differentially regulated in control and AsA 
treated MeWo cells, respectively. All the modulated spots 
were successfully picked up and 29 protein species were 
identified by nano-HPLC-Chip ion trap MS/MS (Table 1). 
In Supplementary Figure 1, the identified protein species 
are marked with the numbers corresponding to the 
standard spot number (SSP) appearing in Table 1. 
Gene ontology and protein interactions analysis 
By bioinformatic analyses, we found that the 
cellular components mostly over-represented in AsA-
treated cells were cell part (25%), organelle (16%) and 
macromolecular complex (8%). As for the molecular 
function category, we found the catalytic activity (29%), 
binding (25%), and structural molecule activity (8%) 
among the most prominent significant GO enriched 
terms. In addition, the GO enrichment analysis suggested 
that proteins modulated by AsA are mainly involved in 
metabolic (50%) and cellular processes (29%), as well as 
in cellular components organization or biogenesis (17%) 
(Figure 2A). By STRING analysis we identified a core 
network of AsA-modulated proteins mainly involved in 
energetic metabolism, structure and folding (ATP5B, 
ENO1, MDH2, PFN1, PPIA, SOD2, TAGLN2 and 
VDAC1) suggesting a key role of AsA in these processes 
(Figure 2B).
Protein-protein functional association in 
apoptosis and metastasis
The reconstruction by STRING of functional 
association in apoptosis showed, as eye-catching 
interaction, that PARK7, NPM1 and STMN1 were 
functionally associated with TP53; ENO1 and NPM1 
with MYC; PTGES3 and SSBP1 with HSF1. PARK7 
was also associated with BCL2L1 and DAXX; NPM1 
with CASP6, and STMN1 with MAPK1. Furthermore the 
results showed interactions between PARK7 and ENO1; 
NPM1 and BCL2L1, DAXX, CASP3, CYC6, YY1; 
finally, ENO1 and CYCS, albeit with a lower strenght 
(Figure 3A; Supplementary Tables 1 and 2). 
As for metastasis, NPM1 and PTGES3 were 
associated with MTOR and AKT1. Besides, NPM1 
interacted with CDK2 and RB1. A lower strength was 
found in the association between PARK7 and ENO1 with 
AKT1; STMN1 with TYMS (Figure 3B; Supplementary 
Tables 3 and 4).
Gene expression modulation and migration 
ability in AsA treated melanoma cells 
We chose to investigate ENO1, PTGES3, NPM1, 
PARK7, STMN1 and SSBP1 gene expression. In fact, it 
has been reported that the above genes show increased 
expression in aggressive tumors, but data related to their 
role in melanoma are either scanty or still lacking. 
Therefore, gene expression was monitored in cells 
treated with 500 µM AsA. Real time RT-PCR results 
showed that ENO1, PTGEs3/p23, NPM1, PARK7/DJ1 
and STMN1/p18 genes expression was lower in AsA 
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treated cells in both cell lines compared to controls (*p 
< 0.05; #p < 0.01). No difference was observed when 
we analyzed SBBP1 gene expression in both cell lines. 
Figure 4A. In addition, both AsA treated cell lines showed 
a lower migration ability compared to untreated cells 
Figure 4B. Likewise gene expression and migration 
ability were evaluated in cells treated with A2P. As shown 
in Supplementary Figure 2 we found similar results even 
if A2P treatment affected cell viability also at a lower 
concentration 
Gene expression analyses and migration ability 
In order to evaluate the involvement of the above 
genes in melanoma malignancy, we analyzed their 
expression levels in cancer and normal cells (melanocytes 
and fibroblasts); we also investigated the relationship 
between gene expression levels and migratory ability. We 
observed that ENO1, PARK7, NPM1 and STMN1 genes 
expression levels were higher in melanoma cells than 
in melanocytes and in normal fibroblasts (Figure 5A). 
In particular, ENO1 and NMP1 expression levels were 
higher in all melanoma lines; PTGS3 expression was 
higher in all cell lines except for Colo853 melanoma cells. 
SSBP1 instead was higher only in Colo853, compared to 
melanocytes and normal fibroblasts. Migration ability, 
evaluated by scratch test (Figure 5B) and expressed as 
relative migration distance (RMD) (Figure 4C), correlated 
with gene expression. Notably a positive correlation 
between NMP1, PTGS3 and PARK7 genes expression 
levels and migratory ability was found; conversely, a 
negative correlation was found between SSBP1 expression 
levels and cells migratory ability. (Figure 5D). 
To confirm the relation between gene expression and 
migration ability we knocked down NMP1and PARK7 in 
A375 and Mewo cell lines by applying NMP1 and PARK7 
specific shRNA sequences, respectively. In NMP1 and 
PARK 7 knock-down cells the expression of the above 
genes was reduced as well as migration ability, compared 
to A375 and Mewo WT cells (Supplementary Figure 3). 
Analysis of SKCM data from cancer genome 
atlas database
On the basis of the proteomic analysis results and 
in a translational-medicine perspective, we applied a 
Figure 1: AsA treatment effects in melanoma cells. (A) After treating A375 and Mewo cells with AsA at 500 and 1000 μM 
concentrations, a statistically significant dose-dependent reduction of cell viability was observed for both cell lines (*p < 0.05; #p < 0.01). 
(B) Representative two-dimensional gel electrophoresis images obtained using a) control and b) AsA treated MeWo cells. (C) Principal 
component analysis of proteome patterns. The two principal components PC1 and PC2 were 22,6% and 19,2%, respectively. The PCA 
scatterplot clearly clustered the individual proteome maps into two distinct groups corresponding to the two experimental groups considered 
(controls and AsA treated cells).
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bioinformatic approach to query about the corresponding 
genes and their involvement in Skin Cutaneous Melanoma 
(SKCM). For this purpose, we used the cBio Genomic 
Cancer Portal [11, 12] which allows to analyze the 
multidimensional harmonized cancer genomic datasets 
(included Cancer Genome Atlas database, TCGA) at 
the gene level. Specific biological events (e.g., mRNA 
expression and protein abundance changes) can be 
detected, networks based on biological pathways 
which involve genes of interest can be generated and 
epidemiological information (e.g. survival analysis) can 
be retrieved. The results showed that all six genes were 
globally altered in 229 of 479 samples queried (47,8%) 
(Figure 6A). Among them, SSBP1 gene was the most 
frequently altered (141/479 = 29%), followed by PARK7 
(56/479), STMN1 (51/479), PTGES3 (44/479), ENO1 
Table 1: Proteins identified by nano-HPLC-Chip ion trap MS/MS
Protein name Gene name Spot no. a) 
(Supplementary 
Figure 1)
NCBI
 acc. #
No. 
peptides 
identified
Mascot 
score 
Mr. (Da) exp./
theor.
pI exp./
theor.
Seq.
 Coverage 
(%)
Fold 
change b)
p (corr) p value
(< 0.01)
Apoptosis:
10 kDa heat shock protein, 
mitochondrial
HSPE1 9004 gi|4504523 18 443 10000/10925 8.8/8.89 76 2.07 0.879 0.0016
adenylate kinase 2, 
mitochondrial
AK2 8202 gi|4502013 5 206 29000/26745 7.8/7.67 21 1.59 0.831 0.0043
Co-Chaperone P23 PTGES3 102 gi|9257073 4 112 20000/15216 4.5/5.09 36 -10 -0.774 0.0056
cyclophilin A PPIA 8103 gi|1633054 9 270 17500/18154 7.8/7.82 35 1.54 0.885 0.0001
manganese superoxide 
dismutase
SOD2 7101 gi|62738405 7 214 22000/21864 7.3/6.86 27 1.64 0.909 0.0007
MICOS complex subunit 
MIC19
CHCHD3 9102 gi|8923390 3 135 27000/26491 8.4/8.48 8 1.82 0.884 0.0007
mitochondrial single-stranded 
DNA binding protein
SSBP1 8002 gi|2624694 5 163 15500/15186 7.8/8.23 36 1.77 -0.809 0.0002
profilin-1 PFN1 9002 gi|4826898  4 207 15000/15258 8.4/8.44 37 1.41 0.804 0.0089
profilin-1 PFN1 9001 gi|4826898 7 193 15000/15258 8.4/8.44 49 1.96 0.978 0.0000
protein DJ-1 PARK7 4108 gi|31543380 6 166 25000/20092 5.9/6.33 33 -1.56 -0.799 0.0038
voltage-dependent anion-
selective channel protein 1
VDAC1 8307 gi|4507879 18 455 35000/30896 8.0/8.62 43 1.79 0.915 0.0004
Cell migration, invasion, 
and metastasis:
alpha-enolase ENO1 5610 gi|4503571 20 641 50000/47566 6.8/7.01 37 -1.54 -0.904 0.0004
alpha-enolase ENO1 5608 gi|4503571 13 492 50000/47566 6.7/7.01 33 -1.54 -0.904 0.0002
B23 nucleophosmin NPM1 1406 gi|825671 6 294 36000/31132 4.7/4.71 25 -1.72 / 0.0021
heat shock protein beta-1 HSPB1 5201 gi|4504517 12 208 28000/22840 6.2/5.98 33 1.31 0.869 0.0004
nuclear corepressor KAP-1 NCOR1 902 gi|1699027 2 79 90000/90682 4.6/5.52 3 -6.25 -0.810 0.0082
phosphatidylethanolamine-
binding protein 1
PEBP1 7107 gi|4505621 3 197 21000/21186 7.6/7.01 22 1.39 0.895 0.0012
transgelin-2 TAGLN2 9101 gi|4507357 10 288 21000/22605 8.4/8.41 32 1.30 0.878 0.0024
Oxidative stress:
albumin ALB 4708 gi|119626083 4 110 60000/58614 5.8/6.66 6 1.87 0.832 0.0018
ATP synthase subunit d, 
mitochondrial
ATP5H 2103 gi|5453559  4 143 21000/18551 5.2/5.21 16 1.55 0.900 0.0002
malate dehydrogenase MDH2 9307 gi|2906146 9 454 36000/36077 9.0/8.92 28 2.95 0.786 0.0085
peroxiredoxin-1 PRDX1 8107 gi|4505591 13 379 23000/22096 8.0/8.27 42 1.42 0.865 0.0030
mRNA processing and 
translation:
40S ribosomal protein S21 RPS21 7004 gi|4506699 2 93 10000/9248 7.6/8.68 33 1.61 0.927 0.0003
elongation factor Tu EFTUD 6501 gi|704416 9 294 49000/49935 6.9/7.7 22 1.58 0.814 0.0078
heterogeneous nuclear 
ribonucleoproteins A2/B1
HNRPA2B1 9312 gi|4504447 4 233 35000/35984 8.2/8.67 14 2.33 / 0.0000
heterogeneous nuclear 
ribonucleoproteins A2/B1 
HNRPA2B1 9313 gi|4504447 4 140 35000/35984 8.6/8.67 14 2.54 0.869 0.0018
heterogeneous nuclear 
ribonucleoproteins A2/B1
HNRPA2B1 8306 gi|4504447 4 250 33000/36055 7.9/8.67 14 2.59 0.868 0.0014
Cytoskeleton organization:
alpha-tubulin TUBA 2707 gi|37492 5 186 55000/50978 5.2/5.02 14 -1.33 -0.837 0.0057
stathmin 1 STMN1 4101 gi|197692339 6 202 17500/17320 5.7/5.76 29 -1.49 -0.813 0.0040
a) Spot numbers refer to those in Supplementary Figure 1 b) Fold change: the expression ratios between the means of spots value (% vol) of control and AsA treated MeWo cells resulting from digital image 
analysis. – Indicates decreased protein intensity.
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(41/479) and, finally, NPM1 (25/479). The alterations 
affecting them tended to take place concomitantly 
(Supplementary Table 5). Relatively to gene expression, 
the enrichment analysis showed a statistically significant 
over-expression of SSBP1 (p-value = 1.09e-33; Q-value = 
1.33e-29), PARK7 (p-value = 8.16e-8; Q-value = 8.35e-7), 
and ENO1 (p-value = 0.041; Q-value = 0.18). Notably, 
SSBP1 resulted to be the first statistically significant within 
the gene list (12,192 entries of 20,532 mRNA) with altered 
mRNA expression in SKCM. When gene co-expression 
was queried, a positive correlation was found between 
PARK7 and ENO1 (Pearson correlation test: 0.43; p-value 
< 2.2e-16), (PARK7 and SSBP1 (Pearson correlation test: 
0.38; p-value < 2.2e-16), PTGES3 and NPM1 (Pearson 
correlation test: 0.30; p-value = 2.463e-11) (Figure 6B). 
As for the enrichment analysis of protein expression, 
data are available only for STMN1 and PARK7 encoded 
proteins (235 entries). Stathmin 1 showed a statistically 
significant (p-value = 1.069e-4; Q-value = 5.024e-3) over-
expression compared to the unaltered group; Deglycase 
DJ-1 tended to be slightly under-expressed, although the 
result was not statistically significant (p-value = 0.783; 
Q-value = 0.876). No result was found for the other gene 
products. No statistically significant correlation was found 
for concurrent protein expression.
Network analysis in SKCM 
In order to unearth the network complexity 
involving the investigated genes and their partners relevant 
to SKCM, we queried the Cbio Portal Network Analysis. 
The cBio Portal generated a network showing that ENO1, 
PTGES3, NPM1 and STMN1 are connected in this tumor 
(Figure 6C). PARK7 and SSBP1, on the contrary, showed 
neither mutual connections nor any connection with the 
previously mentioned genes network
DISCUSSION
Melanoma incidence has been increasing in recent 
times and the prognosis for metastatic melanoma is poor. 
An early detection of skin lesions and surgical treatment 
Figure 2: PANTHER functional classification of differentially expressed proteins between MeWo controls and MeWo 
cells treated with AsA. (A) Histograms showing classification according to cellular component, molecular function, and biological 
process. (B) Schematic view of known and predicted protein interactions according to the STRING database (v. 10). Only interactions with 
the medium confidence score (0.400) are shown. Interactions include physical and functional associations, showing the evidence view. The 
lines indicate co-expression (grey), experimental (pink) or database (cyan) evidences.
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Figure 3: Protein-protein functional associations involved in apoptosis and mestastasis. The figure shows a schematic 
visualization of the action types and action effects concerning ENO1, PARK7, PTGES3, NPM1, SSBP1, STMN1 (pointed by black arrow) 
among themselves and other proteins, known and predicted, to be involved in apoptosis (Protein-Protein Interaction -PPI- enrichment 
p-value < 0,01) (A) and metastasis (PPI enrichment p-value < 0,01) (B), according to the STRING v10.5 (only interactions with confidence 
score >= 0.400 are shown). Line colours and shapes indicate reaction (black), binding (blu), catalysis (indigo), transcriptional regulation 
(green mint), activation (light green), post-translational modification (fuchsia), inhibition (red), positive effect (arrowhead), negative effect 
bar), and unspecified effect (dot). Finally, the thickness of grey lines indicates the strength of data support.
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before cells dissemination represent successful therapeutic 
approaches; after metastases spreading, instead, effective 
tools against melanoma are limited. Despite initial positive 
responses, cells subsequently become resistant to apoptosis 
and chemotherapy. Thus the discovery of new oncotargets 
is essential in order to develop more effective anticancer 
agents. It should also be noted that oncotargets may be 
elicited by molecular changes concerning programmed cell 
death (apoptosis), proliferation, production of new blood 
vessels (angiogenesis), drug resistance, and potential of 
cells to initiate secondary tumors (metastasis) [13]. 
Here we consider a few oncotargets prompted 
by proteomic analysis, which were also supported and 
validated by gene expression and bioinformatic analyses. 
The proteomic results indicate that ascorbic acid down-
modulates proteins involved in cell migration and 
invasiveness. Among these, the most strongly repressed 
protein is co-chaperone P23 (PTGES3, -10). Interestingly 
p23 is degraded during apoptosis induced by several 
stimuli, including Fas and TNFα-receptor activation [14]. 
Furthermore, it has been demonstrated that increased 
p23 expression may confer a more aggressive phenotype 
to cancer cells, promoting drug resistance, motility and 
metastasis [15]. PTGES3 gene is not only involved in 
the prostaglandin biosynthetic process (GO:0001516), 
but also in telomere maintenance (GO:0000723), signal 
transduction (GO:0007165), and xenobiotic metabolic 
process (GO:0006805). P23/TEBP, its product, takes 
part in cellular responses to stress (such as activation of 
Heat shock factor 1, HSF1) (GO:1900034), and is a co-
chaperone of Heat Shock Protein 90 (HSP90). Precisely, 
P23/TEBP addresses the recruitment of prolyl hydroxylase 
domain protein 2 (EGLN1/PHD2) to the HSP90 pathway 
by facilitating HIF alpha proteins hydroxylation via 
Figure 4: Gene expression modulation and migration ability in AsA treated melanoma cells. (A) Gene expression profiles in 
untreated versus AsA treated Mewo and A375 cells. *indicates significant values (p < 0.05) for Mewo cells; §indicates significant values (p 
< 0.05) for A375 cells. (B) The migration ability (expressed as RMD: Rate Migration Distance ) was significantly lower in both melanoma 
cell lines treated with AsA (*p < 0.05; #p < 0.01).
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interaction with EGLN1/PHD2. HSF1 is alterated in 22% 
of samples (102/479, mainly mRNA over-expression) and 
encodes a transcription factor induced after heat shock 
stress to regulate lifespan. The strong down-regulation of 
co-chaperone P23 (-10) following ascorbic acid treatment 
of MeWo cells and the positive correlation between gene 
expression and migratory ability confirm that this protein 
is an important oncotarget on which searches for new 
drugs against melanoma can be addressed.
We also found that nucleophosmin production is 
down-regulated by AsA treatment (NPM1, -1,72); we 
have demonstrated a positive correlation between NPM1 
gene expression and migratory ability, confirmed by RNA 
interference assay, as well. This protein may also represent 
a therapeutic target. Interestingly, it has been shown 
recently that nucleophosmin expression correlates with 
the migration and invasiveness of colon cancer cells [16]. 
In melanoma the over-expression of NPM1 has already 
been confirmed; it has also been reported that this protein 
undergoes hyperphosphorylation [17]. Nucleophosmin 
results to be engaged in various processes such as 
chromosome maintenance (i.e., nucleosome assembly and 
telomerase maintenance), DNA repair (GO:0006281), 
DNA damage response via p53 (GO:0006977), 
intracellular protein (GO:0006886) and nucleocytoplasmic 
(GO:0006913) transport, response to stress (GO:0006950), 
cell aging (GO:0007569), and HIF1 alpha transcription 
factor network. NPM1 gene expression is controlled by 
ARNT (24% of alterations reported, mainly gene over-
expression, in the TCGA SKCM samples), which encodes 
a co-factor for transcriptional regulation by hypoxia-
inducible factor 1. 
We also found DJ-1 protein (PARK7, -1.56) to be 
down-regulated after treatment with AsA. In addition we 
observed also a strong positive correlation between PARK 
7 gene expression and migratory ability in melanoma cell 
line. This relation was confirmed by RNA interference 
assay as PARK7 knockdown reduced the migration 
ability. PARK7 encodes Deglycase DJ-1, a member of the 
peptidase C56 family, that is engaged in various processes 
such as negative regulation of TRAIL-activated apoptotic 
signaling pathway (GO:1903122), protein stabilization and 
Figure 5: Gene expression analyses and migration ability evaluation in normal (fibroblasts and melanocytes) and 
melanoma cells. (A) Stastically significant expression levels are indicated for each gene with *p < 0.05 and #p < 0.01, respectively. (B).
Scratch test for migration ability evaluation (C) Relative Migration Distance values: *p < 0.05), #p < 0.01). (D) Correlation between gene 
expression levels and migration ability in melanoma cell lines. A positive correlation was found for NMP1, PTGS3 and PARK7, while a 
negative correlation was found for SSBP1.
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physiology (GO:0050821), cadherin binding involved in 
cell-cell adhesion (GO:0098641), maintenance of correct 
mitochondrial morphology and function (GO:0007005) 
as well as autophagy of dysfunctional mitochondria [18]. 
It also acts as p53 inhibitor, and by inducing the vHL/
HIF1 and PI3K/AKT/mTOR it promotes invasiveness, 
metastasis and chemotherapy resistance [19]. Furthermore, 
DJ-1 plays a fundamental role in counteracting cell death 
due to oxidative stress (GO:0034599) since it functions as 
an oxidative stress sensor and redox-sensitive chaperone 
and protease.
Alpha enolase, ENO1 gene product, was found to be 
down-regulated by ascorbic acid. It acts on the PI3K/AKT 
signal and correlates with cell invasiveness in various 
Figure 6: Genes involved in SKCM. (A) Graphical summary of genomic alterations in ENO1, PTGES3, NPM1, PARK7, STMN1 and 
SSBP1 across the 479 SKCM samples from TCGA. Globally, the six queried genes are altered in 229/479 SKCM samples (47.8%). Row: 
queried gene and corresponding percentage. Bar: tumour sample. (B) Positive correlation data found for genes coexpression (C) Network 
analysis. Overall view of ENO1, NPM1, PTGES3, STMN1 network interconnections. SSPB1 network does not show any interconnection 
with the above network. No network was reported for PARK7 in SKCM. Each gene pathway is also represented individually. Nodes 
represent queried genes (thick border) and nearest neighbour-genes, which are shown with color-coded alteration frequency in SKCM. 
Edges are color-coded according to the different interaction types.
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cancers [20]. Interestingly, ENO1 promotes invasion and 
metastasis formation also by acting as a plasminogen 
receptor [21]. The alpha enolase/MBP1 protein takes 
part in growth control, hypoxia tolerance processes (it is 
related to the HIF-1 signaling pathway). Moreover, MBP1 
is involved in cell-cell adhesion (GO:0098609), cadherin 
binding involved in cell-cell adhesion (GO:0098641). 
Noteworthy, ENO1 and MYC mutually control 
themselves for mRNA expression. MYC is an important 
regulator of cell cycle progression, apoptosis and cellular 
transformation. In the TCGA database, it is altered in 15% 
(69/479, mainly mRNA over-expression) SKCM samples. 
Interestingly, we found that two protein species of alpha-
enolase are down-regulated in MeWo cells after ascorbic 
acid treatment (both -1.54), confirming a key role of this 
protein as oncotarget in melanoma. 
STMN1, a member of the stathmin gene family, 
encodes the cytosolic phosphoprotein Stathmin 1, which 
plays a role in the regulation of microtubule organization. 
Furthermore, stathmin is involved in cytoskeletal signaling 
and G protein–coupled receptors pathway. STMN1 network 
is connected to PTGES3 via the Ca(2+)/calmodulin-
dependent protein kinase CAMK2B, which belongs to the 
serine/threonine protein kinase family and plays a role in 
different neuronal processes. This protein is involved in 
protein phosphorylation (GO:0006468), MAPK cascade 
(GO:0000165) and signal transduction (GO:0007165). 
Precisely, CAMK2B protein phosphorylates STMN1 and 
HSF1 gene products. Interestingly, STMN1 has been 
reported to be up-regulated during the progression of 
melanoma [22]. To date, STMN1 results also to be over-
expressed across many human cancers, included cutaneous 
squamous cell carcinoma [23], a non melanoma skin 
cancer. This protein may as well represent an oncotarget 
as suggested by its down-regulation (-1.49), observed in 
proteomics analysis of MeWo cells treated with ascorbic 
acid. Finally, as can be noted in Figure 5C, SSBP1 network 
is not connected with ENO1, PTGES3, and NPM1 networks 
in SKCM. SSBP1 encodes MtSSB (mitochondrial single-
stranded DNA-binding protein). This gene is involved 
in trascriptional activaction of mitochondrial biogenesis 
(GO:0007005 as well as GO:0070584). The gene product 
takes part in DNA replication (GO:0006260) as a positive 
regulator of helicase activity (GO:0051096), and is also 
a subunit of a single-stranded DNA (ssDNA)-binding 
complex involved in the maintenance of genome stability 
[24]. The gene resulted quite altered (141/479 = 29%) in 
SKCM; its mRNA expression is regulated by GABPA 
and GABP1. Both genes are involved in the trascriptional 
activation of mitochondrial biogenesis (GO:0007005) 
and regulation of transcription from RNA polymerase 
II promoters (GO:0006357). It is interesting to note that 
GABPA and GABPB1 interact with YY1, which regulates 
MYC gene expression. MtSSB protein is phosphorylated 
by CHEK1 that plays a role in DNA damage checkpoint 
(GO:0000077), G2/M transition of mitotic cell cycle 
(GO:0000086) and DNA repair (GO:0006281). Here we 
found that MtSSB is upregulated in MeWo cells after 
ascorbic acid treatement (+ 1.77). Although it is difficult to 
envision its direct role as a therapeutic target, it should be 
highlighted that this protein protects p53 against ubiquitin 
dependent degradation. Furthermore SSBP1 associates with 
acetyltransferase p300 and promotes p53 acetylation [25]. 
SSBP1 upregulation by ascorbic acid could therefore be 
essential for an effective action of tumor suppressor p53. 
In summary our findings demonstrate that 
an integrated approach involving proteomics, gene 
expression analysis and bioinformatics can be employed 
effectively to discover oncotargets. In particular we found 
that reduced cell viability and migration ability observed 
after AsA treatment in MeWo cells are associated to 
ENO1, PTGES3, NPM1, PARK7 and STMN1 genes 
dowregulation. Consistently, our data showed these genes 
to be overexpressed in melanoma cancer cells compared 
to normal melanocytes and dermal fibroblasts. The strong 
positive correlation between NMP1, PTGES3, PARK7 
genes expression and migration ability suggests their 
involvement in the metastatic process. On the contrary, 
analysis of SSBP1 properties and its negative correlation 
with migration ability uncover an onco-suppressor gene in 
melanoma. In conclusion, the molecules described above, 
and in particular SSBP1 and PARK7, may be considered 
oncotargets suitable for the design of specific drugs or as 
specific molecular tools for the diagnosis and follow up 
in melanoma.
MATERIALS AND METHODS
Cells and AsA treatment
Two melanoma cell lines were used to assay the 
effects of AsA on gene and protein expression. A375 and 
Mewo melanoma cells (at passage 5 and 6 respectively, 
purchased from American Type Culture Collection 
(Rockville, MD, USA, no mycoplasm test was performed)) 
passage were cultured under humidified atmosphere of 
5% CO2 and passaged in growth medium: DMEM/F12 
containing 10% FBS (fetal bovine serum) supplemented 
with antibiotics (1% penicillin and streptomicyn) and 
1% glutamin. Cells were then harvested using trypsin, 
washed and counted on a microscope using a Burker 
hemocytometer and plated again in growth medium. 
AsA was obtained from StemCell Technologies Inc. 
(Vancouver, BC, Canada) and dissolved in sterile water 
at a final concentration of 50 mM. Stock solutions were 
kept at −20°C for long-term storage and protected from 
exposure to light and air to prevent oxidation. Cells were 
also treated with ascorbate-2-phosphate (As2P) (Sigma-
Aldrich; Merck Millipore) for a comparative evaluation. 
Once 80% confluence was reached the cells were 
treated with ascorbic acid at concentrations ranging from 
to 0 to 1,000 μM .
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Cell viability
Cell viability was evaluated by the reduction of 
the tetrazolium salt XTT (sodium 3I-[1-phenylamino- 
carbonyl-3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzene 
sulfonic acid hydrate- Cell proliferation kit II—XTT 
Roche) as previously reported [26]. 
In particular, 100 μl XTT labelling mixture were 
added to control and treated cells mantained at 37 
°C in humidified atmosphere of 5% CO2 for 4 h. The 
spectrophotometric absorbance of the samples was 
evaluated by measuring the microtitre plate (ELISA) 
reader at a wavelength of 450 nm.
2DE proteomics analysis
2DE protein analysis from three biological 
replicates for a total of 1.5 × 106 MeWo cells, untreated 
and treated with 500 µM AsA for 48 h, was performed as 
previously described [27]. Briefly, 500 µg of protein were 
subjected to IEF with 18 cm immobilized nonlinear pH 
3–10 gradient IPG strips using a Protean IEF Cell (Bio-
Rad). After IEF, IPG strips were equilibrated and then the 
proteins were separated using 8–18% SDS-PAGE gels. 
Ruthenium chelate (RuBPs) fluorescent staining was 
used to visualize protein spots on 2DE gel. Gels obtained 
by 2-DE were acquired using the VersaDoc (Bio-Rad 
Laboratories) and analyzed by PDQuest version 7.3 (Bio-
Rad Laboratories), to obtain spot intensity quantification 
and gel matching. Normalized spot volumes were 
subjected to univariate and multivariate statistical analyses 
[28]. First of all an unsupervised Principal Component 
Analysis (PCA) was applied to detect global relationship 
among maps (Simca-P+ 13, Umetrics, Sweden). Then 
a Student’s t test (p < 0.01) was performed by using 
PDQuest, and multivariate statistics by using Simca-P+ 
13 on log-transformed spot volumes. In particular, for 
identification of protein spots separating the two groups, 
we used orthogonal partial least squares discriminant 
analysis (OPLS-DA), applying a variable influence on 
projection (VIP) > 1.5 to identify the protein spots that 
most contributed to the calculated OPLS-DA model.
Protein identification by nano-HPLC-Chip ion 
trap mass spectrometry
Spots were selected for identification based on 
significant differences in Student’t t-test (p < 0.01) and/
or good correlations [p(corr) > 0.75] by the multivariate 
OPLS-DA. Protein identification was performed after 
in-gel trypsin digestion, as previously described [29]. 
Briefly, peptides from each sample were separated by RP 
nano-HPLC-Chip technology (Agilent Technologies, Palo 
Alto, CA, USA) online-coupled with a 3D ion trap mass 
spectrometer (model Esquire 6000, Bruker Daltonics, 
Bremen, Germany). Database searches were conducted 
using the MS/MS ion search of Mascot against human 
entries of the non-redundant NCBI database.
Protein annotation and proteins interactions 
Functional annotation of identified proteins was 
performed according to Gene Ontology (GO) using the 
PANTHER classification system v 9.0 (http://www.
pantherdb.org/) according to cellular components, 
molecular functions and biological processes. Protein 
interactions were assessed using the STRING database 
(http://string-db.org). In addition, STRING analysis 
was performed to reconstruct the functional association 
of ENO1, PARK7, PTGES3, NPM1, SSBP1, STMN1 
among them and other proteins involved in apoptosis and 
metastasis, by querying genes involved in the progression 
and metastatic potential of melanoma reported by Riker 
[30]. We retrieved interactions that were of at least 
medium confidence (score 0.4) based exclusively on 
coexpression, experimental and database knowledge while 
excluding all other prediction methods implemented in 
STRING (such as textmining and gene fusion). Network 
depth was kept to the minimum value (1) and no additional 
white nodes were added in order to exclude as many false 
positive interactions as possible.
Cell cultures 
A total of 5 malignant melanoma lines (A375 (at 
passage 5)), MeWo ((at passage 6)), MEL-HO (at passage 
5), Colo-800 (at passage 4) and Colo-853 (at passage 
5)) plus a melanocyte cell line (NHEM, at passage 2) 
were purchased from American Type Culture Collection 
(Rockville, MD, USA); a dermal fibroblast culture was 
obtained from a skin biopsy of a normal individual 
(control) after appropriate consent. No mycoplasm test 
was performed. Cell lines were cultured in RPMI 1640 
or DMEM (Sigma-Aldrich; Merck Millipore, Darmstadt, 
Germany) with 10% foetal bovine serum (FBS) (Sigma-
Aldrich; Merck Millipore) according to manufacturer’s 
instructions. Adherent cells for each cell line were 
harvested to perform molecular and cellular analyses. For 
each cell line, three different cultures were tested.
Total RNA extraction
Total RNA was extracted by using the RNAeasy 
minikit (Quiagen) with DNAse I and analyzed by 
measuring the absorbance at 260 nm and 280 nm. RNA 
integrity was confirmed by RNA electrophoresis on a 
1.5% agarose gel containing ethidium bromide.
Reverse transcription
First-strand cDNA was obtained by using the 
First Strand cDNA Synthesis Kit (GE Healthcare), with 
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random hexamers, (GE Healthcare) according to the 
manufacturer’s protocol. RT products were stored at 
−80°C.
Real time RT-PCR
PCRs were performed in a total volume of 
25 µl containing PCR Master with ROX premixed 
with SYBR Green and 20 ng of cDNA from each 
sample The following primer sets were used: 
ENO1(FW TAACAACAACCTGAAGAATG -RV-
TCCAGGCCTTCTTTATTCTC) STMN1 (FW-AGATGT 
ACTTCTGGACTCAC-RV GATCAGACCAGGTA 
ATCAATG)-NMP1 (FW-GCCAGTGAAGAAATCTATACG-
RV  TACAGAACTAGGTCCTTTTGG)–(SSBP1 FW-GGTG 
ATGTCAGTCAAAAGAC- RV-TCACATATTGATATGCC 
ACG) - PTGES3 (FW CAGATGATGATTCACAAGACAG-
RV -CTTTAGAGCTATCAACTCAGG)-PARK7 (FW-CTGT 
TGGCTCATGAAATAGG-RV-GTGTAATGACCTCCATTC 
ATC)-
Real Time RT-PCR reactions were carried out 
in two-tube system and in multiplex. The Real Time 
amplifications included 10 minutes at 95°C (AmpliTaq 
Gold activation), followed by 40 cycles at 95°C for 15 
seconds and at 60°C for 1 minute. Thermocycling and 
signal detection were performed with ABI Prism 7300 
Sequence Detector; (Applied Biosystems). Signals were 
detected according to the manufacturer’s instructions. 
Gene expression was calculated after normalization 
against the housekeeping genes (B2M, GAPDH) using 
the relative fold expression differences. Ct values for each 
reaction were determined using TaqMan SDS analysis 
software. For each amount of RNA tested triplicate Ct 
values were averaged.
RNA interference
We analysed the effects of NMP1 and PARK7 
genes knockdown by using MISSION shRNA specific for 
NMP1 (SequenceA: CCGGGCCAAGAATGTGTTGTCC 
AAACTCGAGTTTGG ACAACACATTCTTGGCTTT 
TTG;SequenceB: CCGGGCGCCAGTGAAGAAATCTAT 
AC TCGAGTATAGATTTCTTCACTGGCGCTTT 
TTG;SequenceC: CCGGGCCGACAAAGAT 
TATCACTTTCTCGAGAAAGTGATAATCTTTGTC 
GGCTTTTTG;SequenceD:CCGGCCTAGTTCTGTAGA 
AGACATTCTCGAGAATGTCTTCTACAGAACT 
AGGTTTTTG; PARK7 (SequenceA:CCGGACTCTGAG
AATCGTGTGGAAACTCGAGTTTCCACACGATTCT 
CAGAGTTTTTT;SequenceB: CCGGGCTGGGATTAA 
GGTCACCGTTCTCGAGAACGGTG ACCTTAA
TCCCAGCTTTTT;SequenceC:CCGGGTAGCCGT 
GATGTGGTCATTTCTCGAGAAATGACCACATCA 
CGGCTACTTTTT;Sequence D: CCGGGCAATTGTT 
GAAGCCCT GAATCTCGAGATTCAGGGCTTC 
AACAATTGCTTTTT) and non-targeting controls (control 
and scrambled) (from Sigma-Aldrich (St. Louis, MO)) as 
previously reported [31]. In the following experiments, 
the four sequences for each target were applied combined 
two at a time (shRNA-A and shRNA-B) as previously 
described [31]. Briefly, 1.6 × 104 cells were seeded at low 
density into 96- well plates. After 12 h (cell confluency of 
70%) shRNA Lentiviral Particles supplemented with 8 μg/
ml hexadimethrine bromide was added and then replaced 
after 8 h with normal growth medium. 
Migration ability 
A scratch test was used in order to evaluate 
migration ability. The cells were cultured in 48-well plates 
and grown to 80% confluence. The scratch track was 
produced by using a 200-µl pipette tip. The supernatants 
were removed and the plates were washed with PBS and 
grown in fresh medium. Cell migration was observed 
in timelapse (EVOS) and the relative migration was 
calculated as previously reported [32], i.e. as relative 
migration distance (RMD) (%) = 100 (A–B)/A, with A and 
B representing the width of cell scratches before and after 
incubation, respectively. Images were in 3 independent 
experiments.
Cbio genomics cancer portal analyses
To investigate the involvement of ENO1, 
PARK7, PTGES3, NPM1, SSBP1 and STMN1 in the 
Skin Cutaneous Melanoma (SKCM), we carried out a 
preliminary analysis on these genes by means of the 
open-resource cBio Cancer Genomics Portal (http://www.
cbioportal.org/), using the provisional data set about the 
SKCM (479 samples) stored in the Cancer Genome Atlas 
(TCGA; https://cancergenome.nih.gov/). We analyzed 
the six genes for different genomic profilings such as 
alterations (i.e., amplification, deep deletion, mRNA and 
protein expression changes, and missense mutations), 
mRNA expression (RNA Seq V2 RSEM), and Protein 
expression (Reverse phase protein array, RPPA). To 
analyze mRNA and protein expression, we used the 
default z-score threshold ± 2 both RNA Seq V2 RSEM 
and RPPA, respectively. Furthermore, we investigated 
whether events involving such queried genes happen in 
a way of mutual exclusivity or co-occurrence in order to 
contribute to development and progression of SKCM. The 
enrichment analysis was used to find mRNA expression 
changes and, if available, protein expression changes. We 
also took into account the expression correlation among 
them.
Finally, to locate the interacting genes and the 
pathways engaging the query genes in SKCM, we looked 
for the network involving ENO1, PARK7, PTGES3, 
NPM1, SSBP1 and STMN1. In fact, the cBio Portal 
offers the possibility to generate automatically networks 
containing the query genes and their alterated neighbour-
Oncotarget11501www.impactjournals.com/oncotarget
genes in the type of investigated cancer. Usually, the 
generated network shows only 50 neighbour-genes with 
the highest genomic alteration frequency in addition to 
the query genes. This entails the advantage of managing 
network complexity and automatically drawing attention 
to the most relevant genes, thanks to the visualization of 
networks which are altered into the cancer type of interest. 
Statistical analysis
Results were expressed as mean ± S.E. Statistical 
analysis was assessed by one-way analysis of variance 
(ANOVA). Differences between groups yielding a 
statistical significance with p < 0.05 were tested with 
Bonferroni as a post hoc test. Analyses were applied to 
experiments carried out at least three times. Statistical 
analyses were performed using SPSS for Windows, 
version 16.0 (SPSS Inc, Chicago, IL, USA).
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